Demographic and clinical characteristics of the study cohorts
| IBD (n=10) | RA (n=15) | PsA (n=12) | P values* | P values† | |
| Age, years (mean±SD) | 46.0±9.7 | 55.5±17.1 | 54.7±17.2 | 0.06 | 0.20 |
| Female, n (%) | 9 (90.0) | 13 (86.7) | 4 (33.3) | 0.80 | 0.01 |
| Disease duration, years (mean±SD) | 13.2±9.9 | 0.8±0.9 | 0.8±0.2 | <0.001 | <0.001 |
| TJC44 (mean±SD) | 4.8±2.5 | 9.1±9.5 | 5.0±3.2 | 0.64 | 0.85 |
| SJC44 (mean±SD) | 4.0±2.3 | 9.0±9.3 | 4.0±2.6 | 0.28 | 0.91 |
| DAS (mean±SD) | 3.4±0.7 | 3.6±1.3 | 3.0±0.4 | 0.89 | 0.16 |
| CD/UC, n (%) | 6 (60.0)/4 (40.0) | – | – | – | – |
| Partial Mayo score (mean±SD) | 2.5±1.3 | – | – | – | – |
| Harvey-Bradshaw score (mean±SD) | 2.8±1.0 | – | – | – | – |
| ESR, mm/first hour (mean±SD) | 43.5±22.7 | 48.6±26.6 | 26.6±39.9 | 0.66 | 0.06 |
| CRP, mg/L (mean±SD) | 20.9±44.3 | 19.9±23.1 | 16.7±29.2 | 0.34 | 0.70 |
| ANA positivity, n (%) | 9 (90.0) | 2 (13.3) | 5 (41.7) | <0.001 | 0.02 |
| IgA-RF positivity, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – |
| IgM-RF positivity, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – |
| ACPA positivity, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – | – |
| Anti-TNF exposure, years (mean±SD) | 2.5±1.6 | – | – | – | – |
| Infliximab/adalimumab, n(%) | 5 (50.0)/5 (50.0) | – | – | – | – |
| Concomitant c-DMARDs, n(%) | 4 (40.0) | 0 (0.0) | 0 (0.0) | – | – |
*Patients with IBD versus patients with RA.
†Patients with IBD versus patients with PsA.
Bold values indicates p<0.05.
ACPA, anticitrullinated peptides antibodies; CD, Crohn’s disease; CRP, C-reactive protein; DAS, Disease Activity Score; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; IBD, inflammatory bowel disease; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; TNF, tumour necrosis factor; UC, ulcerative colitis.